Tego Science, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Seoul Korea, Republic of (2001)

Organization Overview

First Clinical Trial
2018
NCT03668028
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Tego Science, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

fibroblast (1 trial)

Drugs in Phase 2 Trials (1)

allogeneic fibroblasts (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Rotator Cuff Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2